"description","rationale","uuid:ID","name","label","id"
"The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","40c78fbf-d0f3-46b9-9211-8ecaec7f5e18","Study Design 1","","StudyDesign_1"
